LCAT and chronic kidney disease: For another aspect, hepatic Apo A-I gene expression and hepatic lecithin cholesterol acyl transferase (LCAT) mRNA expression are downregulated during the course of CKD, and then this change attributes to a lower plasma Apo A-I level and decreased LCAT activity [58, 59].